EXPOSE Study: Exosomal microRNA Signature for Preoperative Staging in Colon Cancer
This observational study, called EXPOSE, is looking for 400 participants with colon cancer to help develop a new diagnostic test. The goal is to find a way to more accurately identify patients with aggressive colon cancer (pathological stage IIB or higher) before surgery. This information could help doctors decide if neoadjuvant chemotherapy (chemotherapy given before surgery) would be beneficial. Researchers are testing two diagnostic methods: the EXPOSE assay (which uses small RNA sequencing of exosomal microRNAs) and the EXPOSE RT-qPCR panel (which quantifies exosomal microRNAs). The study aims to see if these tests can predict a patient's pathological stage IIB or higher status one year after surgery. You may be eligible if you have confirmed colon cancer, have had or will have surgery, and have available preoperative blood samples and clinical data.
- Study design
- This is an observational study planning to enroll 400 participants with colon cancer.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint is measured at one year after surgery.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
An Exosomal microRNA Signature for Preoperative Staging in Colon Cancer
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Ajay Goel, PhD · PRINCIPAL_INVESTIGATOR · City of Hope Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Pathological Stage IIB or higher patientsAt time of pathology (1year after surgery)